The Serotonin Syndrome, Triptans, and the Potential for Drug–Drug Interactions
Authors:
- Stewart J. TepperSTStewart J. Tepper
- 13 February 2007
- journal article
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 47 (2) , 266-269
Abstract
The serotonin syndrome is an acute adverse reaction to medications that enhance serotonergic activity. The severity of cases ranges from mild to fatal. Recently, the U.S. Food and Drug Administration issued an alert that the risk of developing serotonin syndrome may be increased by the concomitant administration of triptan medications with certain other medications. However, a review of published data does not allow an accurate assessment of such risks related to triptans. We conclude that it is currently unclear whether administration of triptans with other serotonergic medications increases the risk of serotonin syndrome.Keywords
This publication has 10 references indexed in Scilit:
- Coprescription of Triptans With Potentially Interacting Medications: A Cohort Study Involving 240 268 PatientsHeadache: The Journal of Head and Face Pain, 2003
- Role of 5-HT2 receptors in the tryptamine-induced 5-HT syndrome in ratsBehavioural Pharmacology, 2002
- CorrespondenceBritish Journal of Anaesthesia, 2002
- Pathophysiological role of the serotonin system in malignant hyperthermiaBritish Journal of Anaesthesia, 2001
- Migraine Polypharmacy and the Tolerability of Sumatriptan: A Large-Scale, Prospective StudyCephalalgia, 1999
- Lack of Pharmacokinetic and Pharmacodynamic Interaction between Rizatriptan and ParoxetineThe Journal of Clinical Pharmacology, 1999
- The serotonin syndrome and its treatmentJournal of Psychopharmacology, 1999
- Sumatriptan Contraindications and the Serotonin SyndromeAnnals of Pharmacotherapy, 1998
- Co‐administration of fluoxetine and sumatriptan: the Canadian experienceActa Psychiatrica Scandinavica, 1997
- Serotonin Syndrome Complicating Migraine PharmacotherapyCephalalgia, 1996